U.S. markets open in 1 hour 37 minutes
  • S&P Futures

    3,619.25
    +17.75 (+0.49%)
     
  • Dow Futures

    28,981.00
    +180.00 (+0.62%)
     
  • Nasdaq Futures

    11,052.25
    +16.75 (+0.15%)
     
  • Russell 2000 Futures

    1,686.90
    +17.10 (+1.02%)
     
  • Crude Oil

    82.88
    +3.39 (+4.26%)
     
  • Gold

    1,673.80
    +1.80 (+0.11%)
     
  • Silver

    19.44
    +0.40 (+2.11%)
     
  • EUR/USD

    0.9762
    -0.0039 (-0.40%)
     
  • 10-Yr Bond

    3.8040
    0.0000 (0.00%)
     
  • Vix

    31.86
    +0.02 (+0.06%)
     
  • GBP/USD

    1.1204
    +0.0038 (+0.34%)
     
  • USD/JPY

    144.9450
    +0.2160 (+0.15%)
     
  • BTC-USD

    19,212.06
    +12.94 (+0.07%)
     
  • CMC Crypto 200

    436.73
    -6.69 (-1.51%)
     
  • FTSE 100

    6,859.69
    -34.12 (-0.49%)
     
  • Nikkei 225

    26,215.79
    +278.58 (+1.07%)
     

Provention Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference

·2 min read

RED BANK, N.J., Sept. 6, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate virtually in a corporate presentation at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12th at 7:00am EST.

(PRNewsfoto/Provention Bio, Inc.)
(PRNewsfoto/Provention Bio, Inc.)

The presentation will be webcast live and can be accessed by visiting the Events and Webcasts section of the Company's website: http://investors.proventionbio.com/events. The webcast will be archived on the Company's website for 30 days following the presentation.

About Provention Bio, Inc.: 

Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases. The Biologics License Application (BLA) for teplizumab, its lead investigational drug candidate, for the delay of progression to Stage 3 clinical type 1 diabetes in at-risk individuals has been filed by the U.S. Food and Drug Administration (FDA). The Company's pipeline includes additional clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.

Internet Posting of Information:

Provention Bio, Inc. uses its website, www.proventionbio.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation F.D. Such disclosures will be included on the Company's website in the "News" section. Accordingly, investors should monitor this portion of the Company's website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

Investor Contact:
Robert Doody, VP, Investor Relations
rdoody@proventionbio.com
484-639-7235

Media Contact:
Kaelan Hollon, VP, Corporate Communications
khollon@proventionbio.com
202-421-4921

 

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/provention-bio-to-present-at-the-hc-wainwright-24th-annual-global-investment-conference-301618538.html

SOURCE Provention Bio, Inc.